Sogroya Side Effects
Generic name: somapacitan-beco
Note: This document contains side effect information about somapacitan-beco. Some of the dosage forms listed on this page may not apply to the brand name Sogroya.
Applies to somapacitan-beco: subcutaneous solution
Very common (10% or more): Elevated phosphate (17.5%)
Common (1% to 10%): Elevated creatine phosphokinase, blood creatinine kinase increase, weight increased
Common (1% to 10%): Sleep disorder, dizziness
Frequency not reported: Severe hypersensitivity[Ref]
Very common (10% or more): Back pain (10%)
Common (1% to 10%): Arthralgia[Ref]
Common (1% to 10%): Anemia[Ref]
Frequency not reported: Neoplasms[Ref]
Common (1% to 10%): Peripheral edema
Frequency not reported: Increased mortality in patients with acute critical illness[Ref]
Common (1% to 10%): Hypertension[Ref]
Frequency not reported: Lipohypertrophy, lipoatrophy[Ref]
Common (1% to 10%): Tonsillitis[Ref]
Medically reviewed by Drugs.com. Last updated on Nov 29, 2021.
More about Sogroya (somapacitan-beco)
- During Pregnancy
- Dosage Information
- Drug Interactions
- Drug class: growth hormones
- FDA Approval History
Related treatment guides
1. "Product Information. Sogroya (somapacitan)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.